NanoViricides Inc. (NNVC)

[changes_iv]

The Company's drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. ("TheraCourR"), to which the Company has exclusive licenses in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. On February 15, 2010, the Company entered into an Additional License Agreement with TheraCour granting the Company the exclusive licenses in perpetuity for technologies developed by TheraCour for the additional virus types of Dengue viruses (DENV), Japanese Encephalitis (JEV), West Nile Virus (WNV), viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes, and Ebola/Marburg viruses.

What is an exclusive license?

License limited to a specific scope or field, such as context, market, territory, or time. 'Exclusive' does not mean 'one and only' license granted, but only that the licensor agrees not to grant other licenses that have the same rights within the scope or field covered by the exclusive license. It may refer to a geographical area, technological application, method of production, or production of a specific product. Exclusivity may or may not include competition from other licensees or the licensor itself, granting of sublicenses, performance requirements to be met by the licensee, and/or a time limitation. The licensor, in fact, can issue any number of licenses with different rights in the same scope, or licenses with same rights in different scopes. Under copyright law, the licensee of an exclusive license is the owner of a particular right out of several rights constituting a copyright. He or she has the legal power to take court action against anyone who infringes the licensed rights within his or her scope or field. ~
Read more: www.businessdictionary.com/definition/exclusive-license.html#ixzz38PovRmhH

Corporations have many hostile takeover defense mechanisms at their disposal. Given the level of hostile corporate takeovers that have taken place in the U.S. during the first part of this century, it may be prudent for management to put in place preemptive corporate takeover mechanisms, even if their company is not currently being considered for acquisition. Such policies should be seriously pursued by companies that have a well-capitalized balance sheet, a conservative income statement that exhibits high profitability, an attractive cash flow statement and a large or growing market share for its products or services. In addition, if the company exhibits significant barriers to entry, a lack of competitive rivalry in the industry, a minimal threat of substitute products or services, minimal bargaining power of the buyers and minimal bargaining power of the suppliers, the case for implementing preemptive hostile strategies while developing a thorough understanding of responsive takeover defense mechanisms is highly advised.
www.investopedia.com/articles/investing/041913/warding-hostile-takeovers.asp

IMO, TheraCour Pharma, Inc., Dr. Anil R. Diwan, will keep control of the exclusive licensing and rightfully so in order to protect intellectual property exclusively licensed to NanoViricides, Inc.. It is his, and his close associates, R&D that made NanoViricides, Inc. nanoviricides, possible. May God grant the "good doctors" health (without it, nothing else matters) in order to live life to the fullest extent possible and put to good use their individual fortunes.

I am of the opinion that our small, medium and large fortunes will be realized thanks to NanoViricides, Inc. "paradigm-shifting technology". Good news are forthcoming, soon!

Throughout the history of the world, the average person on earth has been extremely poor: subsisting on the modern equivalent of $3 per day. This was true until 1800, at which point average wages—and standards of living—began to rise dramatically. Prof. Deirdre McCloskey explains how this tremendous increase in wealth came about. In the past 30 years alone, the number of people in the world living on less than $3 per day has been halved. The cause of the economic growth we have witnessed in the past 200 years may surprise you. It's not exploitation, or investment. Innovation—new ideas, new inventions, materials, machinery, organizational structures—has fueled this economic boom. Prof. McCloskey explains how changes in Holland and England in the 1600s and 1700s opened the door for innovation to take off—starting the growth that continues to benefit us today.

==================================================

Economics professor Josh Hall describes how greater economic freedom leads to higher incomes and more economic development over time. When governments allow citizens the freedom to trade, own property, create businesses, and contract with others, the income of average citizens grows over time. This effect can be observed internationally when comparing countries, as well as domestically when comparing states in the US.